ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA reported revenue of $19.64 million for fiscal year 2022, down 11.5% from fiscal year 2021, and net income of -$29.88 million.
Figures from company filings; latest fiscal year ended December 31, 2022.
No profile data available.